29 June 2026
Illuminating SYK function in thrombosis and gastrointestinal cancer through independent research
The recording of our June 18 opnMe seminar is now available to stream. Explore complementary medicinal chemistry and biology perspectives on BI 1002494, a highly potent and selective SYK inhibitor available free of charge on opnMe.
Boehringer’s Florian Montel and Matthias Hoffmann open the seminar by describing the discovery of BI 1002494 and the opnMe approach to supporting independent research through free access to preclinical molecules. Teresa Gagliano, of the University of Udine, then explains how an unbiased high-throughput screen of the full opnMe molecule library unexpectedly identified SYK as a promising target in gastrointestinal neuroendocrine tumors (GI-NETs)1. Finally, Brian Storrie, of the University of Arkansas for Medical Sciences, shows how BI 1002494 selectively suppresses thrombosis (occlusive clot formation) without impairing hemostasis (physiological wound healing)2.
Stream the recording now and find inspiration for your own research.
Subscribe to our newsletter to stay updated on our regular additions to opnMe.com.
About opnMe:
opnMe.com, the open science portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. Our molecules are provided to the scientific community either free of charge as “Molecules to Order” or applied for via scientific research submissions as “Molecules for Collaboration”. With our “opn2EXPERTS” and “techMATCH” programs, we enlist scientific advice on key scientific topics to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our "opn2TALENTS" PostDoc grants at one of our research sites offer opportunities for high-level talents to propose innovative approaches for precisely defined scientific questions.
About opnMe online seminars:
We invite you to watch the recordings of our past opnMe online seminars on the following topics:
- Disease models: How opnMe helped advancing Crohn’s Disease and Systemic Sclerosis research
- SOS1 inhibitor: How BI-3406 advanced cancer and diabetes research
- GR agonist: How BI 653048 impacted pancreatic cancer research
- opn2TALENTS: How opnMe is advancing scientific careers
- Optogenetics: Mapping new circuits to analyze neuronal networks in mental health
- CatC: Novel roles of Cathepsin C in human disease
- MMP-13 antagonist: Assessing MMP-13 functions in osteoarthritis and aortic aneurysm
- PROTAC ACBI1: Illuminating the role of SMARCA2/4 in childhood cancer
- BCL6 Degrader: Elucidating the mechanism of small molecule induced protein degradation
References:
- Ditsiou A., Toffoli L., Vella V., D'Este F., Gagliano T. Spleen tyrosine kinase (SYK) inhibition suppresses growth of gastrointestinal neuroendocrine tumor cells: a pilot study in two cell lines. Cancer Gene Ther. 2025, 32(12):1303-1306. DOI: 10.1038/s41417-025-00979-5.
- Faruque M. O., Pokrovskaya I. D., Ball K. K., Webb M. W., Rhee S. W., Storrie B. The Syk inhibitor BI 1002494 impairs thrombus infill in a murine femoral artery occlusion without affecting hemostasis Blood Vessel Thromb Hemost. 2025, 2(4):100108. DOI: 10.1016/j.bvth.2025.100108.